Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI
about
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsEvaluation of paraoxonase, malondialdehyde, and lipoprotein levels in patients with asymptomatic cholelithiasis.Paraoxonases function as unique protectors against cardiovascular diseases and diabetes: Updated experimental and clinical data.Association of vWA and TPOX polymorphisms with venous thrombosis in Mexican mestizos.Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patientsNew antithrombotics for secondary prevention of acute coronary syndrome.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Genetically Determined Platelet Reactivity and Related Clinical Implications.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.Relationships between PON1 Q192R polymorphism and clinical outcome of antiplatelet treatment after percutaneous coronary intervention: a meta-analysis.Clopidogrel Response Variability in Unruptured Intracranial Aneurysm Patients Treated with Stent-Assisted Endovascular Coil Embolization : Is Follow-Up Clopidogrel Response Test Necessary?Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population.
P2860
Q26822796-798C77F1-2C66-4DF3-869F-FD171A0F0A90Q30441413-66B5010A-6A76-461D-9E93-65B22050F1B0Q30829280-74B86BFA-1C9E-44DC-9F66-0F3ECCD04094Q34181424-BB547B22-EE43-44F9-A258-BF612158A8A3Q35921906-ECBF410A-715E-4976-8005-53D889AECE17Q37605071-68D52CFC-7164-45AB-9049-BE7E8859DA58Q38180991-34F75CC6-A2F6-4D84-9576-57AA77F65912Q38307535-FCFF40BE-4D0F-4F85-A83A-464EB670D265Q38489014-D6B23775-BB5F-4449-8B2E-357F3E69F592Q39249688-561C011E-F592-47D2-8CC8-226A0CC79DEBQ48252102-8744A039-C36D-4745-BCA7-E45BC7FAD8D1Q48851836-A7EF7E22-CB23-47FE-95C2-26B2142D96A4Q53079748-0A95771F-896C-4E3F-AC20-43340187D15FQ55471692-65652AB1-5BE1-45C6-B818-608C7C88C274
P2860
Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@ast
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@en
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@nl
type
label
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@ast
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@en
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@nl
prefLabel
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@ast
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@en
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@nl
P2093
P2860
P50
P1433
P1476
Paraoxonase 1 gene polymorphis ...... ith clinical outcome after PCI
@en
P2093
Bon-Kwon Koo
Han-Mo Yang
Hyo-Soo Kim
Hyun-Jae Kang
Jeehoon Kang
Jin Joo Park
Ki-Hyun Jeon
Kyung Woo Park
Sang Eun Lee
Si-Hyuck Kang
P2860
P304
P356
10.1371/JOURNAL.PONE.0052779
P407
P577
2013-01-01T00:00:00Z